Opioid-free anesthesia (OFA) is noninferior to opioid-sparing anesthesia (OSA) for managing pain after laparoscopic cholecystectomy, and it leads to faster bowel recovery. In a randomized controlled trial with 81 adults, pain scores over 36 hours were similar between groups (area under the curve 7.3 for OFA vs. 6.9 for OSA; the difference was 0.384, below the noninferiority threshold of 1.0). Although early pain in the first 12 hours after PACU discharge was slightly higher with OFA, overall pain control was sufficient in both groups. Bowel recovery occurred sooner with OFA (13.8 vs. 15.5 hours). Other outcomes, including hemodynamics and patient satisfaction, were comparable.
Ofatumumab, a fully humanized anti-CD20 antibody, reduced disease activity and disability progression in Chinese patients with relapsing multiple sclerosis. Among 38 treatment-naïve patients, the annualized relapse rate fell from 0.27 to 0.05, and the median disability score dropped from 2.50 to 2.00 after 12 months. Among 59 patients who switched from oral therapies (teriflunomide, siponimod, fingolimod, dimethyl fumarate) due to disease progression, relapse, or MRI activity, the relapse rate decreased from 0.45 to 0.08 and disability scores improved from 2.00 to 1.00. No new MRI lesions, relapses, or serious adverse events occurred in either group.